circRNA basic information
circBase ID: hsa_circ_0018744
Name: hsa_circ_DDIT4
Synonym: circDDIT4
Host Gene: DDIT4
Genomic location(hg19): chr10:74033914-74035797:+
Genomic location(hg38): chr10:72274156-72276039:+
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0008315
MONDO name: prostate cancer
Disease details: prostate cancer
Disease DO ID:
10283
Disease MeSH ID:
D011471
Disease NCIt ID:
C7378
Disease ICD11 ID:
-
Disease OMIM ID:
-
Species: Human
Species details: Homo sapiens
Tissue specimen:

prostate cancer tissues; adjacent normal prostate tissues; serum

Cell lines:

WPMY-1; LNCaP; 22Rv1; DU145; C4-2B; PC-3; C4-2; HEK293T

In vivo animal model:

cell line-derived xenograft

circRNA-disease information
Expression pattern:
DN
Associated gene: ELAVL1/HuR, ANO7, WTAP, METTL3, METTL14, FTO, HNRNPD, SART3, FUBP2, PUF60
Associated microRNA: -
Biological function: Promotes apoptosis and inhibits proliferation, migration/metastasis, and tumor growth in prostate cancer (tumor suppressor).
Molecular mechanism: circDDIT4 acts as an RBP sponge by competitively binding ELAVL1/HuR via its 3′-UTR, thereby reducing ELAVL1 target mRNA stability/expression (including ANO7); its biogenesis is promoted by m6A modification mediated by WTAP/METTL3/METTL14 and inhibited by FTO demethylation.
Biological pathway or process:

apoptosis (promotes); proliferation (inhibits); migration (inhibits); metastasis (inhibits); m6A modification (other); mRNA stability (inhibits)

Detected method:
Q
B
Validation methods:

RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Northern Blot; Nuclear-Cytoplasmic Fractionation; RNase R Treatment; Actinomycin D / DRB Stability Assay; RNA-seq; Clinical Sample Validation; Transfection; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; MeRIP / MeRIP-seq; Co-IP; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; In Vivo Animal Model

Clinical significance:

Lower circDDIT4 expression in prostate cancer tissues and serum suggests circDDIT4 as a potential biomarker or therapeutic target for prostate cancer.

Description:

circDDIT4 is down-regulated in prostate cancer tissues, serum, and cell lines and acts as a tumor suppressor. Mechanistically, circDDIT4 sponges the RBP ELAVL1/HuR via its 3′-UTR, reducing ELAVL1-dependent expression/stability of targets such as ANO7, thereby promoting apoptosis and inhibiting proliferation and migration/metastasis. Its circularization/biogenesis is promoted by WTAP/METTL3/METTL14-mediated m6A modification and antagonized by FTO.

Confidence score:

0.8524

Other information
Title:

m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR.

Journal: Molecular cancer research : MCR
Published: 2023
PubMed ID: 37647111
Study type:

combined biological and clinical study

Data availability: The data generated in this study are available upon request from the corresponding author.
Code availability: -